Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 3314
Journal of Biotechnology & Biomaterials received 3314 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Engineered Erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia
Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry
Iris Munhoz Costa, Debora Custodio Moura, Adalberto Pessoa Jr. and Gisele Monteiro
University of Sao Paulo, Brazil
Posters & Accepted Abstracts: J Biotechnol Biomater
Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent neoplasm in children and adolescents. Treatment of the disease is performed with L-asparaginase (ASNase), an enzyme obtained from the bacteria Escherichia coli and Erwinia chrysanthemi (Erwinase). ASNase hydrolyzes L-asparagine and prevents tumor cells from obtaining this amino acid from the bloodstream for protein synthesis, leading to ALL cell death by apoptosis. However, both formulations are associated with a high rate of adverse effects as the production of anti-asparaginase antibodies and hypersensitivity, which compromise the efficacy of the treatment. The development of mutant proteoforms from commercially available bacterial enzymes may contribute to the development of an enzyme with lower adverse effects. Therefore, we created a mutant library using the ASNase of E. chrysanthemi by error prone PCR, and a double mutant proteoform (DM) presented higher specific activity for L-asparagine and a 30% increase in the kcat in relation to the wild-type (WT) enzyme. In addition, DM enzyme showed less recognition by anti-asparaginase antibodies and is able to kill the same amount of ALL cell line MOLT-4 than WT enzyme, using a smaller amount of protein. The results indicated that the DM enzyme has cytotoxic potential and may have fewer adverse effects.Biography
Iris Munhoz Costa is a PhD student in the graduate program in Pharmaceutical Technology-Biochemistry in the School of Pharmaceutical Sciences at University of São Paulo. She works with biopharmaceutical research for the treatment of acute lymphoblastic leukemia. She has obtained her Master’s degree in Pharmaceutical Technology-Biochemistry at University of São Paulo in 2015; Graduation in Pharmacy and Biochemistry at Universidade Paulista in 2012. She was a student of scientific initiation in the Department of Pharmaceutical Biochemical Technology in the Faculty of Pharmaceutical Sciences at the University of São Paulo in the area of molecular biology and antioxidant response in 2011.
E-mail: iris.munhoz@hotmail.com
